No Data
No Data
Qingdao Haier Biomedical Co., Ltd. (688139.SH): The transfer price of this inquiry is 30.09 yuan/share.
Qingdao Haier Biomedical Co., Ltd. (688139. SH) announced on August 7th that based on the inquiry and application for subscription on August 7th, 2024, the preliminary transfer price for this inquiry is determined to be RMB 30.09 per share.
Qingdao Haier Biomedical Co., Ltd. (688139.SH): Shareholders plan to transfer 2% of their shares through inquiry-based pricing.
On August 6, Gelonhui reported that the shareholder who intends to participate in the pre-IPO shareholding inquiry transfer of Haier Biomedical (688139.SH) is Qijun Equity Investment Partnership Enterprise (Limited Partnership) of Meishan Bonded Port Area, Ningbo. The total number of shares to be transferred by the transferring party is 6,359,050 shares, accounting for 2.00% of the total share capital of the company. This inquiry transfer will not be conducted through centralized bidding or bulk trading, and is not a shareholding reduction through the secondary market. The transferee of the shares acquired through the inquiry transfer shall not transfer them within 6 months after acquisition.
Qingdao Haier Biomedical Co., Ltd. (688139.SH): The company has repurchased 0.26% of its shares.
Qingdao Haier Biomedical Co., Ltd. (688139.SH) announced on August 1st that as of July 31, 2024, the company has repurchased 815,617 shares through the Shanghai Stock Exchange trading system by means of centralized bidding trading, accounting for 0.26% of the total share capital of the company, with the highest repurchase price of RMB 32.31/share, the lowest price of RMB 27.40/share, and a total amount of RMB 25,654,978.48 (excluding transaction fees).
Is There Now An Opportunity In Qingdao Haier Biomedical Co.,Ltd (SHSE:688139)?
Qingdao Haier Biomedical's Unit Ups Stake in Subsidiary
Qingdao Haier Biomedical Co., Ltd. (688139.SH) plans to spend 21.8076 million yuan to acquire 2.53% equity of its subsidiary Haier Blood Technology (Chongqing).
Qingdao Haier Biomedical Co., Ltd., a wholly-owned subsidiary of Haier Biomedical (688139.SH), announced that...
No Data